BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35868873)

  • 1. Hepatic Angiosarcoma Post-Renal Transplantation: A Case Report.
    Tong SH; Huang YJ; Yang YC; Lin HC; Jou YC
    Transplant Proc; 2022; 54(6):1597-1600. PubMed ID: 35868873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report.
    Detroyer D; Deraedt K; Schöffski P; Hauben E; Lagrou K; Naesens M; Delforge ML; Kuypers D
    Transpl Infect Dis; 2015 Apr; 17(2):303-7. PubMed ID: 25645490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of ileal ulcers caused by immunosuppressants in two organ transplant recipients.
    Guo YW; Gu HY; Abassa KK; Lin XY; Wei XQ
    World J Gastroenterol; 2016 Jun; 22(24):5616-22. PubMed ID: 27350740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arteriovenous graft in kidney transplant patients: Lookout for the rare but fearsome angiosarcoma.
    Figueiredo AC; Leal R; Rodrigues L; Romãozinho C; Escada L; Sá H; Figueiredo A; Alves R
    J Vasc Access; 2020 Nov; 21(6):1049-1052. PubMed ID: 31856637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus.
    Nunes Ficher K; Dreige Y; Gessolo Lins PR; Nicolau Ferreira A; Toniato de Rezende Freschi J; Linhares K; Stopa Martins S; Custodio L; Cristelli M; Viana L; Wagner Santos D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Nakamura M; Rosso Felipe C; Medina Pestana J; Tedesco Silva H
    Transplantation; 2022 Feb; 106(2):381-390. PubMed ID: 33988338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
    Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Influence of Everolimus on Mycophenolic Acid Area Under the Concentration-Time Curve: Limited Sampling Strategy for Mycophenolic Acid in Japanese Kidney Transplant Recipients Treated With Tacrolimus, Mycophenolate Mofetil, Steroid, and Everolimus.
    Endo T; Ishimura T; Nishioka S; Yokoyama N; Ogawa S; Fujisawa M
    Transplant Proc; 2022 Mar; 54(2):286-292. PubMed ID: 35034789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
    Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney transplantation in hereditary coproporphyria using tacrolimus and mycophenolate mofetil: a case report.
    Telkes G; Pusztai A; Földes K; Langer RM
    Transplant Proc; 2013; 45(10):3703-4. PubMed ID: 24315002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
    Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
    Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary hepatic angiosarcoma and liver transplantation: Radiological, surgical, histological findings and clinical outcome.
    Tran Minh M; Mazzola A; Perdigao F; Charlotte F; Rousseau G; Conti F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):17-23. PubMed ID: 28416360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.
    Okumi M; Unagami K; Hirai T; Shimizu T; Ishida H; Tanabe K;
    Int J Urol; 2017 Mar; 24(3):197-204. PubMed ID: 27862344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.